Business Context and Reporting Period
This Form 8-K is a current report filed by OncoGenex Pharmaceuticals, Inc. (noted as "ACHIEVE LIFE SCIENCES, INC." in metadata, but the filing text identifies OncoGenex) on January 6, 2010. The registrant is incorporated in Delaware with principal executive offices in Bothell, Washington. The report discloses a material event under Regulation FD regarding a clinical study grant.
Key Financial Metrics
The filing text does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity. This report focuses solely on a regulatory disclosure event rather than financial performance metrics.
Material Changes
The material change disclosed is the announcement that a randomized, investigator-sponsored Phase 2 study evaluating the company's product candidate, OGX-427, has received grant funding. This information was disseminated via a press release dated January 6, 2010.
Guidance, Outlook, and Risks
Management Commentary: The company highlighted the receipt of grant funding for the OGX-427 Phase 2 study as a significant development.
Risks and Contingencies: The filing includes a standard disclaimer stating that the information in this report and its exhibits shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, nor incorporated by reference into other filings, except as expressly set forth by specific reference.
Investor Verification Checklist
- Verify the details of the grant funding for the OGX-427 Phase 2 study in the attached press release (Exhibit 99.1).
- Confirm the current status of the OGX-427 clinical trial program.
- Review subsequent filings for any financial impact or updates related to this grant.
- Note the discrepancy between the metadata company name ("ACHIEVE LIFE SCIENCES, INC.") and the registrant name in the filing text ("ONCOGENEX PHARMACEUTICALS, INC.").